Publication | Closed Access

The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma

Hematological MalignancyLymphoid NeoplasiaMedicineMalignant Blood DisorderImmunologyPathologyImmune Checkpoint InhibitorAutoimmunityAdult T-cell Leukemia-lymphomaImmunotherapyVivo ModelsTumor MicroenvironmentTumor Biology